| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
5-HT1A Receptor 2.6 nM (Ki) Dopamine D2 Receptor 0.49 nM (Ki) Dopamine D3 Receptor 0.085 nM (Ki)
Dopamine D3 receptor (antagonist/partial agonist, Ki: 0.085 nM for D3 in cariprazine); Dopamine D2L receptor (antagonist/partial agonist, Ki: 0.49 nM). Cariprazine-d6 has no independent pharmacological activity as an internal standard. |
|---|---|
| ln Vitro |
As the parent compound, Cariprazine binds with high affinity to dopamine D3 (Ki = 0.085 nM) and D2L (Ki = 0.49 nM) receptors, acting as a partial agonist/antagonist. It also has moderate affinity for 5-HT1A (Ki = 2.6 nM) and is an antagonist at 5-HT2B (Ki = 0.58 nM) with potent antimanic effects. As a stable isotope-labeled internal standard, Cariprazine-d6 has no independent activity.
|
| ln Vivo |
Cellular activity data for the deuterated form are not specifically reported. The non-deuterated Cariprazine is an antipsychotic agent that acts as a dopamine D3 and D2 receptor partial agonist/antagonist. It has demonstrated efficacy in treating schizophrenia and bipolar mania through modulation of dopaminergic and serotonergic signaling pathways in the central nervous system.
|
| Enzyme Assay |
Radioligand binding assays for dopamine D3 and D2 receptors are performed using membrane preparations from CHO cells expressing human dopamine receptors. [3H]-spiperone is used as the radioligand. Cariprazine (non-deuterated) is the reference standard for which Ki values (0.085 nM for D3, 0.49 nM for D2L) are derived from competition curves. Cariprazine-d6 is not used in these assays.
|
| Cell Assay |
Cariprazine-d6 is not used in cell-based assays. For bioanalytical method development, typical protocols involve LC-MS/MS analysis. Biological samples (plasma, serum, or tissue homogenates) are spiked with Cariprazine-d6 as an internal standard at a fixed concentration (e.g., 10-100 ng/mL). Samples are processed by protein precipitation with acetonitrile or methanol, followed by solid-phase extraction (SPE) or liquid-liquid extraction (LLE). The supernatant is injected onto a reverse-phase C18 column with a mobile phase of water/acetonitrile containing 0.1% formic acid. Detection is by MRM in positive ion mode, using specific transitions for Cariprazine and Cariprazine-d6 (mass shift due to 6 deuterium atoms). Peak area ratios are used for quantification.
|
| Animal Protocol |
Pharmacokinetic (PK) studies in animals and humans utilize Cariprazine-d6 as the bioanalytical internal standard. For in vivo studies in rats or dogs, Cariprazine is administered intravenously or orally. Serial blood samples are collected over 24-72 hours. Plasma samples are processed with Cariprazine-d6 as described above. PK parameters such as Cmax, tmax, t1/2, AUC, CL, and Vd are calculated from the concentration-time curve using non-compartmental analysis.
|
| ADME/Pharmacokinetics |
Cariprazine-d6 is the deuterated version of Cariprazine, designed as an internal standard. As a stable isotope-labeled version of Cariprazine, it mimics the physicochemical properties of the non-labeled drug but has no independent pharmacokinetic profile. In LC-MS/MS quantification, it elutes at the same retention time as Cariprazine, allowing for accurate quantification of the parent drug without isotopic interference.
|
| Toxicity/Toxicokinetics |
Cariprazine-d6 is not a therapeutic agent and is not subjected to toxicology studies. The non-deuterated Cariprazine (brand name Vraylar, Reagila) is an FDA-approved atypical antipsychotic for schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, and as an adjunctive treatment for major depressive disorder. Common side effects include akathisia, extrapyramidal symptoms, weight gain, and somnolence.
|
| References | |
| Additional Infomation |
Cariprazine-d6 is a stable isotope-labeled internal standard used exclusively for research and pharmaceutical analysis. The parent drug Cariprazine was first approved by the FDA in 2015. The deuterated version facilitates accurate quantitation in pharmacokinetic studies, therapeutic drug monitoring, and bioequivalence studies, and is used for analytical method development and validation during the drug development and manufacturing process.
|
| Molecular Formula |
C21H26D6CL2N4O
|
|---|---|
| Molecular Weight |
433.45
|
| Exact Mass |
432.232
|
| CAS # |
1308278-67-2
|
| Related CAS # |
Cariprazine;839712-12-8;Cariprazine-d8;1308278-50-3
|
| PubChem CID |
76287256
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
600.1±55.0 °C at 760 mmHg
|
| Flash Point |
316.7±31.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
5.18
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
491
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])N(C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C([2H])([2H])[2H]
|
| InChi Key |
KPWSJANDNDDRMB-WFGJKAKNSA-N
|
| InChi Code |
InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/i1D3,2D3
|
| Chemical Name |
3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-bis(trideuteriomethyl)urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3071 mL | 11.5354 mL | 23.0707 mL | |
| 5 mM | 0.4614 mL | 2.3071 mL | 4.6141 mL | |
| 10 mM | 0.2307 mL | 1.1535 mL | 2.3071 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
